$122MSeries A, 16 October 2025
Funds take lead ADC candidate ADCX-020 into first-in-human trials, with IND and CTA filings by end 2025.
- Amount
- $122M
- Stage
- Series A
- Announced
- 16 October 2025
- Lead
- Bpifrance (Large Venture, InnoBio)
- Other investors
- Kurma Partners, Andera Partners, Angelini Ventures, Surveyor Capital, aMoon, Pontifax, DawnBiopharma, Pureos Bioventures, RA Capital
- Use of funds
- Funds take lead ADC candidate ADCX-020 into first-in-human trials, with IND and CTA filings by end 2025.
- Checked
- Announced by the company
- Sources
- Adcytherix raises 105M euros Series A for antibody-drug conjugates biospace.com
Adcytherix raises 105M euros Series A for antibody-drug conjugates fusacq.com